University of Calgary Validates Biosenta’s Tri-Filler™ Antimicrobial Technology with Over 200x Enhanced Performance

University of Calgary Research Confirms Major Antimicrobial Performance Enhancements

Collaborative research at the University of Calgary has provided laboratory evidence validating Biosenta’s Tri-Filler™ technology. Testing revealed the antimicrobial material delivers over 200 times greater antibacterial performance than calcium hydroxide, a widely used antimicrobial agent in industrial and medical applications.

The research team was led by Dr. Maen Husein from the Schulich School of Engineering and Dr. Mehdi Mohammadi Ashani from the Department of Biological Sciences, with contributions from Dr. Reza Lashkari and Dr. Noora Darwish. This joint effort involved the University of Calgary, Biosenta, and the Alberta Centre for Advanced Diagnostics, underscoring a multi-institutional collaboration to advance the technology from lab research toward commercial use.

Long-Term Stability Tests Support Product Development

Beyond antibacterial effectiveness, the research addressed whether Tri-Filler maintains its protective properties over extended periods in demanding conditions. Early results indicate the material preserved both its structural integrity and antimicrobial capabilities after over one year of exposure to high temperature and humidity.

This durability is crucial for applications requiring resistance to environmental stress without performance loss. Dr. Mehdi Mohammadi Ashani, Senior Scientist at Biosenta and University of Calgary researcher, noted the collaborative work extends beyond initial lab tests to evaluate Tri-Filler’s long-term performance, generating data vital for product development and regulatory submissions—key steps toward commercializing medical and industrial antimicrobial products.

Tri-Filler™ Technology Design and Target Markets

Biosenta’s Tri-Filler™ is a proprietary core-shell antimicrobial nanotechnology designed for integration into coatings, paints, concrete, and other building materials in high-contact environments. Its controlled-release mechanism aims to deliver sustained antimicrobial protection without frequent reapplication or surface treatments.

Potential applications identified by Biosenta and the University of Calgary include hospitals, schools, daycares, and public transit systems—settings where reducing microbial contamination is critical for health and operational safety. The technology’s versatility suggests it could serve multiple market segments upon successful commercialization.

Biosenta’s Commercialization Roadmap and Upcoming Milestones

Biosenta’s announced commercialization plan involves ongoing product validation, manufacturing scale-up, regulatory engagement, and strategic partnerships to facilitate market entry. President and CEO Am Gill emphasized that independent validation from the University of Calgary bolsters the scientific foundation of Tri-Filler and that collaboration with research partners will continue throughout the commercialization process.

The company anticipates that field testing will yield structured data and insights to guide product refinement, partner relations, and broader market adoption. This phased approach—from laboratory validation to field trials and regulatory processes—aligns with standard pathways for launching novel antimicrobial materials in regulated sectors like healthcare and construction.

History of Research Collaboration and Technology Advancement

Biosenta has partnered with the University of Calgary research team over several years to evolve Tri-Filler from laboratory innovation to commercial readiness. This extended collaboration indicates iterative development and rigorous testing prior to achieving independent peer-reviewed validation.

The multi-year joint effort among academic researchers, Biosenta’s scientific and business teams, and the Alberta Centre for Advanced Diagnostics exemplifies a coordinated strategy to transition nanotechnology from concept to practical application. While specific timelines for regulatory approval, manufacturing scale-up, and market launch remain undisclosed, these activities are integral to the company’s forward-looking plans.

Independent Validation as a Key Commercial Milestone

Third-party scientific validation is a strategic asset for companies commercializing innovative products. The University of Calgary’s research provides independent credibility for Tri-Filler’s performance claims, potentially aiding discussions with manufacturing partners, regulators, and customers.

Am Gill described the validation from one of Canada’s premier research institutions as "an important milestone for Tri-Filler," highlighting its significance in Biosenta’s commercialization journey. However, no details were provided regarding timing for regulatory filings, manufacturing agreements, or product launch.

Context Within the Antimicrobial Nanotechnology Industry

The development of antimicrobial nanotechnologies reflects growing industry demand for durable surface protection, especially in healthcare, food service, and public environments where microbial contamination poses risks. Tri-Filler’s core-shell and controlled-release design offers a solution for maintaining long-lasting antimicrobial effects without frequent maintenance.

The announcement does not compare Tri-Filler to competing technologies, nor does it detail regulatory timelines or market size estimates. Investors should consider seeking further information on competitive positioning, intellectual property, and regulatory progress to evaluate Biosenta’s commercial potential.

Company Overview and Research Infrastructure

Biosenta develops innovative antimicrobial products providing environmentally friendly solutions globally. Headquartered in Toronto, Ontario, and Calgary, Alberta, the company supports both research and business development activities. Its proprietary nanoparticle technology offers durable protection against a broad spectrum of bacteria, molds, and fungi, though specific efficacy data beyond Tri-Filler’s disclosed results were not included.

The dual-location setup enables close collaboration with research partners such as the University of Calgary and the Alberta Centre for Advanced Diagnostics, while maintaining access to Toronto’s financial markets for business and investor relations.

Investor Considerations and Forward-Looking Statements

The announcement contains forward-looking statements highlighting that Biosenta’s business, financial condition, and operational results may be influenced by risks related to product development, regulatory approval, manufacturing scale-up, and market acceptance. The company advises against undue reliance on these statements, which reflect conditions only as of the announcement date.

Immediate effects on the company’s share price were not evident from public information. Prospective investors should review Biosenta’s financial disclosures, intellectual property filings, and regulatory status to assess commercialization risks and timelines for potential revenue generation from Tri-Filler and other antimicrobial products in development.